Search results
Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study
Zacks via Yahoo Finance· 5 days agoData from a late-stage study shows that transfusion-dependent thalassemia patients who received...
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
Motley Fool via Yahoo Finance· 13 hours agoIntellia Therapeutics Intellia doesn't have products on the market yet, but the company is getting...
Gene therapy and employee benefits: from science fiction to medical reality
BenefitsPRO· 6 days agoAt the rate research and approvals have been accelerating, the 2020s may be remembered as the decade...
Agios Pharmaceuticals' blood disorder drug succeeds in late-stage study
Reuters· 7 days ago, opens new tab said on Monday its experimental treatment for an inherited blood disorder met the main goal in a late-stage study. The drug candidate, mitapivat, significantly ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 7 days ago– Study Achieved the Primary Endpoint; Mitapivat Demonstrated a Statistically Significant Transfusion Reduction Response Compared to Placebo – – Statistical Significance Achieved for All Key Secondary Endpoints Evaluating Additional Measures
Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) the Leading Gene Therapy Stock to Buy Now?
Insider Monkey via Yahoo Finance· 6 days agoWe recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we...
Why Is Agios Pharmaceuticals Stock Trading Higher On Monday? - Agios Pharmaceuticals (NASDAQ:AGIO)
Benzinga· 6 days agoShares Agios Pharmaceuticals Inc.’s AGIO climbed after it was revealed a Phase 3 ENERGIZE-T study of...
These Biotech Stocks Hit New Highs, Did You Reap The Rewards?
RTT News· 2 days agoThe following compilation represents a selection of stocks featured on our website that reached new 52-week high levels during the current week. Protagonist is a clinical-stage biopharmaceutical ...
Agios Pharmaceuticals Shares Rise 16% After Positive Trial Data for Mitapivat
Market Watch· 6 days agoAgios Pharmaceuticals shares were up 16% to $42 after the company said its global Phase 3 study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 2 days agoThe drug, now known as Casgevy, will cost $2.2 million for a single treatment. But uptake remains to...